Qamar, Arman

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., et al. (2018) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 265

Prescription of glucagon-like peptide-1 receptor agonists by cardiologists.

Vaduganathan, M., Patel, R. B., Singh, A., McCarthy, C. P., Qamar, A., Januzzi, J. L., Scirica, B. M., Butler, J., Cannon, C. P., & Bhatt, D. L. (2019) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 55

Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk

Bhatia, K., Jain, V., Gupta, K., Bansal, A., Fox, A., Qamar, A., Damman, K., & Vaduganathan, M. (2021) · European Journal of Heart Failure

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 30

Risk factors for myocardial infarction in very young South Asians

Gupta, M. D., Gupta, P., MP, G., Roy, A., & Qamar, A. (2020) · Current Opinion in Endocrinology, Diabetes & Obesity

Cardiovascular Health and Risk FactorsDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 27

Targeting RNA to lower triglycerides: long strides from short molecules

Qamar, A., Libby, P., & Bhatt, D. L. (2019) · European Heart Journal

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 14